News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,475 Results
Type
Article (13761)
Company Profile (101)
Press Release (251613)
Section
Business (88299)
Career Advice (465)
Deals (15396)
Drug Delivery (66)
Drug Development (36722)
Employer Resources (49)
FDA (6310)
Job Trends (6209)
News (150700)
Policy (14085)
Tag
Academia (444)
Alliances (23297)
Alzheimer's disease (378)
Approvals (6336)
Artificial intelligence (93)
Bankruptcy (146)
Best Places to Work (4380)
Breast cancer (70)
Cancer (525)
Cardiovascular disease (54)
Career advice (406)
Cell therapy (73)
Clinical research (30879)
Collaboration (289)
Compensation (116)
COVID-19 (758)
C-suite (100)
Data (539)
Diabetes (74)
Diagnostics (1347)
Drug discovery (50)
Drug pricing (61)
Earnings (32024)
Events (37436)
Executive appointments (325)
FDA (6649)
Funding (181)
Gene therapy (92)
GLP-1 (326)
Government (1285)
Healthcare (3618)
Infectious disease (787)
Inflammatory bowel disease (54)
Interviews (59)
IPO (5891)
Job creations (2057)
Job search strategy (372)
Layoffs (176)
Legal (3438)
Lung cancer (72)
Manufacturing (129)
Medical device (1334)
Medtech (1336)
Mergers & acquisitions (9657)
Metabolic disorders (224)
Neuroscience (533)
NextGen: Class of 2025 (1585)
Non-profit (601)
Northern California (628)
Obesity (124)
Opinion (116)
Patents (91)
People (28819)
Pharmaceutical (64)
Phase I (8035)
Phase II (13076)
Phase III (11723)
Pipeline (312)
Policy (54)
Postmarket research (1403)
Preclinical (3205)
Radiopharmaceuticals (120)
Rare diseases (148)
Real estate (2643)
Regulatory (10073)
Research institute (571)
Resumes & cover letters (55)
Southern California (625)
Startups (1633)
United States (6250)
Vaccines (136)
Weight loss (89)
Date
Today (56)
Last 7 days (284)
Last 30 days (1090)
Last 365 days (12493)
2025 (2121)
2024 (12627)
2023 (14332)
2022 (19635)
2021 (20145)
2020 (19093)
2019 (14948)
2018 (11777)
2017 (13950)
2016 (13172)
2015 (15518)
2014 (12525)
2013 (10662)
2012 (11450)
2011 (12020)
2010 (10984)
Location
Africa (314)
Asia (20050)
Australia (2597)
California (1500)
Canada (813)
China (195)
Colorado (61)
Connecticut (64)
Delaware (49)
Europe (39866)
Florida (264)
Illinois (166)
Indiana (120)
Japan (76)
Kansas (53)
Maryland (226)
Massachusetts (1301)
Minnesota (82)
New Jersey (639)
New York (422)
North Carolina (352)
Northern California (628)
Pennsylvania (374)
South America (501)
Southern California (625)
Texas (197)
Virginia (62)
Washington State (101)
265,475 Results for "nls pharmaceutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
June 28, 2024
·
6 min read
Drug Development
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments
NLS Pharmaceutics Ltd. today announced preclinical results from multiple in vitro studies targeting alpha-synuclein specifically the A53T mutation, that demonstrate the compounds’ potential to advance the treatment of Parkinson’s Disease (PD).
June 27, 2024
·
6 min read
Press Releases
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
November 5, 2024
·
10 min read
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will attend the BIO-EUROPE Springtime Partnering Event taking place March 18-20, 2024.
March 14, 2024
·
1 min read
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO).
June 11, 2024
·
7 min read
Deals
Nasdaq Panel Grants NLS Pharmaceutics’ Request for Extension to Comply with Continued Listing Requirements
NLS Pharmaceutics Ltd. announced today that it received notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.
June 25, 2024
·
4 min read
Press Releases
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
October 28, 2024
·
1 min read
Drug Development
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
NLS Pharmaceutics Ltd. today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami.
May 28, 2024
·
6 min read
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
NLS Pharmaceutics Ltd. announced that it has been notified by the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company’s plan to regain compliance submitted on February 23, 2024 has been approved.
March 11, 2024
·
4 min read
Business
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS”), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the “License Agreement”) with Aexon Labs, Inc., a U.S.-based biotech firm (“Aexon”).
March 20, 2024
·
9 min read
1 of 26,548
Next
